Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

FBRX
Forte Biosciences, Inc. Common Stock
stock NASDAQ

Market Open
Jul 9, 2026 1:57:47 PM EDT
32.52USD+58.017%(+11.94)3,248,391
27.45Bid   37.28Ask   9.83Spread
Pre-market
Jul 9, 2026 9:28:30 AM EDT
21.25USD+3.256%(+0.67)188,708
After-hours
Jul 8, 2026 4:00:30 PM EDT
20.58USD-0.049%(-0.01)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 1, 2021
10:55AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Oct 25, 2021
11:20AM EDT  Overview Of Value Stocks In The Healthcare Sector   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
07:30AM EDT  Chardan Capital Upgrades Forte Biosciences to Neutral, Lowers Price Target to $3.5   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 13, 2021
10:27AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 9, 2021
06:16PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. (Forte or the Company) (NASDAQ: FBRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 6, 2021
10:27AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Sep 5, 2021
01:14PM EDT  The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week   Benzinga
Sep 3, 2021
03:26PM EDT  Mid-Afternoon Market Update: Crude Oil Down 1%; MongoDB Shares Jump After Q2 Results   Benzinga
02:31PM EDT  Why Forte Biosciences Stock Is Down Over 80% Today   Benzinga
12:03PM EDT  Mid-Day Market Update: Gold Rises 1%; Forte Biosciences Shares Plunge   Benzinga
11:50AM EDT  Brookline Capital Downgrades Forte Biosciences to Hold   Benzinga
10:10AM EDT  Mid-Morning Market Update: Markets Mostly Lower; US Economy Adds 235,000 Jobs In August   Benzinga
08:28AM EDT  Chardan Capital Downgrades Forte Biosciences to Sell, Announces $4 Price Target   Benzinga
08:00AM EDT  Ladenburg Thalmann Downgrades Forte Biosciences to Neutral   Benzinga
06:45AM EDT  Shares of Forte Biosciences, Inc. (FBRX) fell more than 80 percent as the company reported on Thursday that the topline data from its phase 2 trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint. Based on the data, the company said it will not continue to advance FB-401.   RTTNews
06:41AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT).   RTTNews
06:01AM EDT  A Peek Into The Markets: US Stock Futures Rise; All Eyes On Jobs Report   Benzinga
05:38AM EDT  B. Riley Securities Downgrades Forte Biosciences to Neutral, Announces $3 Price Target   Benzinga
05:37AM EDT  Truist Securities Downgrades Forte Biosciences to Hold   Benzinga
Sep 2, 2021
04:08PM EDT  Forte Biosciences Announces The Clinical Trial Of FB-401 For The Treatment Of Atopic Dermatitis Failed To Meet Statistical Significance   Benzinga
04:05PM EDT  Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance   Business Wire
Aug 17, 2021
05:52AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.37 A.M. EDT).   RTTNews
Aug 16, 2021
04:05PM EDT  Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7   Business Wire
Aug 2, 2021
04:01PM EDT  Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules   Business Wire
Jun 23, 2021
12:21PM EDT  Forte Biosciences Publishes Clinical Trial 'Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study' To ClinicalTrials.Gov Site   Benzinga
May 14, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 14, 2021   Benzinga
06:25AM EDT  B. Riley Securities Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $73   Benzinga
May 10, 2021
05:09PM EDT  Forte Biosciences, Inc. - Common Stock Q1 EPS $(0.36) Beats $(0.52) Estimate   Benzinga
04:06PM EDT  Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update   Business Wire
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 3, 2021
04:30PM EDT  Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update   Business Wire
Mar 26, 2021
10:23AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 26, 2021   Benzinga
08:33AM EDT  Citigroup Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $75   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
08:20AM EDT  Forte Biosciences, Inc. - Common Stock Q4 EPS $(0.37)   Benzinga
08:12AM EDT  Forte Biosciences Q4 Loss/shr Narrows To $0.37 From $0.74 Prior Year   RTTNews
08:00AM EDT  Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update   Business Wire
Mar 17, 2021
04:05PM EDT  Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update   Business Wire
10:25AM EDT  Forte Biosciences Shares Spike Higher; Chardan Research Lowers Price Target From $115 To $105; Says 'A Blue SKies FB-401 Success In AD Implies ~$192-$839/Share'   Benzinga
10:08AM EDT  Chardan Capital Maintains Buy on Forte Biosciences, Lowers Price Target to $105   Benzinga
Feb 23, 2021
04:01PM EST  Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th   Business Wire
Feb 18, 2021
04:01PM EST  Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st   Business Wire
Feb 12, 2021
04:01PM EST  Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules   Business Wire
Nov 24, 2020
04:05PM EST  Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd   Business Wire
Nov 16, 2020
04:05PM EST  Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules   Business Wire
Nov 10, 2020
04:05PM EST  Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th   Business Wire
Nov 9, 2020
04:17PM EST  Forte Biosciences, Inc. - Common Stock Q3 EPS $(0.45) Beats $(0.54) Estimate   Benzinga
04:05PM EST  Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update   Business Wire
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 2, 2020
04:30PM EST  Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9   Business Wire
04:05PM EST  Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
Oct 29, 2020
08:15AM EDT  Forte Biosciences Prices Underwritten Public Offering Of 1.4 Mln Shares At $28.50/shr   RTTNews
08:13AM EDT  Forte Biosciences Announces Pricing Of $40.0 Million Public Offering Of Common Stock At $28.50/Share   Benzinga
08:00AM EDT  Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock   Business Wire
Oct 28, 2020
04:35PM EDT  Forte Biosciences Announces Proposed Public Offering of Common Stock; Size Not Disclosed   Benzinga
04:09PM EDT  Forte Biosciences Announces Proposed Public Offering of Common Stock   Business Wire
Oct 26, 2020
08:39AM EDT  Forte Biosciences Says US FDA Grants Fast Track Designation To FB-401 For Treatment Of Atopic Dermatitis   RTTNews
08:32AM EDT  Forte Biosciences, Inc. Announces FDA Has Granted Fast Track Designation To FB-401 For The Treatment Of Atopic Dermatitis   Benzinga
Oct 16, 2020
09:00AM EDT  Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules   Business Wire
Sep 29, 2020
09:10AM EDT  Forte Says First Patient Dosed In Trial Of FB-401 For Treatment Of Children And Adults With Atopic Dermatitis   RTTNews
09:00AM EDT  Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis   Business Wire
Sep 24, 2020
08:57AM EDT  Chardan Capital Maintains Buy on Forte Biosciences, Raises Price Target to $110   Benzinga
Sep 9, 2020
04:01PM EDT  Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine   Business Wire
Aug 28, 2020
03:19PM EDT  Why Forte Biosciences's Stock Is Trading Higher Today   Benzinga
12:24PM EDT  Brookline Capital Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $90   Benzinga
09:17AM EDT  Chardan Capital Upgrades Forte Biosciences to Buy, Announces $45 Price Target   Benzinga
Aug 25, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For August 25, 2020   Benzinga
08:33AM EDT  Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules   Benzinga
08:30AM EDT  Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules   Business Wire
07:33AM EDT  Truist Securities Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $70   Benzinga
Aug 10, 2020
04:05PM EDT  Forte Biosciences Q2 Loss/share $9.52 Vs. Loss $0.30 Year Ago   RTTNews
04:01PM EDT  Forte Biosciences, Inc. - Common Stock Q2 EPS $(9.52) Down From $(0.30) YoY   Benzinga
04:00PM EDT  Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update   Business Wire
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 3, 2020
09:00AM EDT  Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10   Business Wire
Jul 28, 2020
08:30AM EDT  Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC